Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kathrin R Frey"'
Publikováno v:
Endocrine Connections, Vol 7, Iss 6, Pp 811-818 (2018)
Context: Patients with primary adrenal insufficiency (PAI) or congenital adrenal hyperplasia (CAH) receive life-long glucocorticoid (GC) therapy. Daily GC doses are often above the physiological cortisol production rate and can cause long-term morbid
Externí odkaz:
https://doaj.org/article/46e3d5a6d48c48ac99e30424f453d297
BclI polymorphism of the glucocorticoid receptor and adrenal crisis in primary adrenal insufficiency
Publikováno v:
Endocrine Connections, Vol 6, Iss 8, Pp 685-691 (2017)
Context: Patients with primary adrenal insufficiency (PAI) or congenital adrenal hyperplasia (CAH) are at a high risk of adrenal crisis (AC). Glucocorticoid sensitivity is at least partially genetically determined by polymorphisms of the glucocortico
Externí odkaz:
https://doaj.org/article/d100989ad0ff45639de208921c66c9dc
Autor:
Ann-Cathrin Koschker, Stefanie Hahner, Silke Horn, Almuth Meyer, Carmina Teresa Fuss, Kathrin R Frey, Stephanie Burger-Stritt
Publikováno v:
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-6 (2020)
Endocrinology, Diabetes & Metabolism Case Reports
Endocrinology, Diabetes & Metabolism Case Reports
Summary Standard treatment of hypoparathyroidism consists of supplementation of calcium and vitamin D analogues, which does not fully restore calcium homeostasis. In some patients, hypoparathyroidism is refractory to standard treatment with persisten
Publikováno v:
Endocrine Connections
Endocrine Connections, Vol 7, Iss 6, Pp 811-818 (2018)
Endocrine Connections, Vol 7, Iss 6, Pp 811-818 (2018)
Context Patients with primary adrenal insufficiency (PAI) or congenital adrenal hyperplasia (CAH) receive life-long glucocorticoid (GC) therapy. Daily GC doses are often above the physiological cortisol production rate and can cause long-term morbidi
Autor:
Julia Schulz, Mark S. Cooper, Kathrin R Frey, Marcus Quinkler, Sven Diederich, Manfred Ventz, Kathrin Zopf
Publikováno v:
European Journal of Endocrinology. 174:531-538
ObjectiveIndividuals with primary adrenal insufficiency (PAI) or congenital adrenal hyperplasia (CAH) receive life-long glucocorticoid (GC) replacement therapy. Current daily GC doses are still higher than the reported adrenal cortisol production rat